Studies have shown that targeting and inhibiting αvβ3 or FAK/Src (such as the small molecule inhibitor PF-562271) may be one of the effective ways to slow down lung cancer (Wu et al., 2022). This evidence concerns the gene PTK2 and lung carcinoma.